Free Trial

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics logo
$21.04 +0.60 (+2.94%)
As of 09:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Intellia Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
2
Hold
6
Buy
13

Based on 21 Wall Street analysts who have issued ratings for Intellia Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 2 have given a sell rating, 6 have given a hold rating, and 13 have given a buy rating for NTLA.

Consensus Price Target

$27.95
32.84% Upside
According to the 21 analysts' twelve-month price targets for Intellia Therapeutics, the average price target is $27.95. The highest price target for NTLA is $60.00, while the lowest price target for NTLA is $7.00. The average price target represents a forecasted upside of 32.84% from the current price of $21.04.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NTLA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NTLA Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
13 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$27.95$29.05$33.37$61.77
Forecasted Upside32.84% Upside140.90% Upside200.08% Upside243.35% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

NTLA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NTLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intellia Therapeutics Stock vs. The Competition

TypeIntellia TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.52
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside40.03% Upside1,396.74% Upside10.49% Upside
News Sentiment Rating
Neutral News

See Recent NTLA News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/6/2025Citizens Jmp
0 of 5 stars
 UpgradeMarket PerformOutperform$33.00+65.33%
10/6/2025JMP Securities
3 of 5 stars
Silvan Tuerkcan
Silvan Tuerkcan
1 of 5 stars
UpgradeMarket PerformMarket Outperform$33.00+65.33%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (D-)
9/19/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$25.00 ➝ $30.00+86.22%
8/13/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00+28.91%
8/11/2025Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$68.00 ➝ $60.00+456.07%
8/8/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$50.00 ➝ $45.00+292.67%
8/8/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$25.00 ➝ $21.00+95.90%
6/16/2025Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$7.00-20.98%
6/3/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$74.00 ➝ $54.00+654.19%
5/9/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$14.00 ➝ $10.00+19.33%
4/21/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer PerformOutperform$21.00+190.46%
3/4/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$90.00 ➝ $50.00+457.10%
2/28/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$55.00 ➝ $26.00+157.68%
2/28/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutralSell$9.00-17.13%
2/28/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweightNeutral$45.00 ➝ $13.00+19.71%
1/27/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightEqual Weight$56.00 ➝ $11.00+0.09%
1/13/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$60.00 ➝ $40.00+300.40%
1/10/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$70.00 ➝ $50.00+334.78%
11/18/2024William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$14.00-0.21%
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$24.00 ➝ $18.00+13.56%
9/11/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$80.00 ➝ $64.00+218.09%
8/9/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$65.00 ➝ $65.00+156.11%
11/10/2023Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$78.00 ➝ $57.00+136.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:30 AM ET.


NTLA Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Intellia Therapeutics is $27.95, with a high forecast of $60.00 and a low forecast of $7.00.

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares.

According to analysts, Intellia Therapeutics's stock has a predicted upside of 32.84% based on their 12-month stock forecasts.

Over the previous 90 days, Intellia Therapeutics's stock had 2 upgrades by analysts.

Intellia Therapeutics has been rated by research analysts at Chardan Capital, Citizens Jmp, Guggenheim, HC Wainwright, JMP Securities, Royal Bank Of Canada, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Intellia Therapeutics more than other "medical" companies. The consensus rating for Intellia Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how NTLA compares to other companies.


This page (NASDAQ:NTLA) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners